Active Antithrombin (AT) Homo sapiens (Human) Active protein

AT3; ATIII; SERPINC1; Anti-Thrombin Antibodies; Serpin Peptidase Inhibitor Clade C Member 1; Coding Sequence Signal Peptide Antithrombin Part 1

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Pointn/a
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Antithrombin (AT) Packages (Simulation)
  • Active Antithrombin (AT) Packages (Simulation)
  • APC313Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Antithrombin III, also known as Serpin C1, is a member of the Serpin superfamily of the serine protease inhibitors. It is the principal plasma Serpin of blood clotting proteases and inhibits thrombin as well as several factors such as Xa. Similar to Serpins A5 and D1, its thrombin inhibitory activity is enhanced by heparin. Hereditary and acquired Serpin C1 deficiency is the cause of an increased thrombotic tendency in many cases. For example, acquired Serpin C1 deficiency is a common condition in sepsis, after major trauma or surgery. The activity of recombinant human antithrombin III was measured by its ability to inhibit thrombin cleavage of a fluorogenic peptide substrate Boc-VPR-AMC in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5. Thrombin was diluted to 0.5 U with heparin at 50 µg/ml in the assay buffer and 10 ul different concentrations of recombinant human antithrombin III (MW: 50 KD) was incubated with 10 ul diluted thrombin at 37 ℃ for 30 minutes. Loading 50 µL of the incubated mixtures which were diluted five-fold in assay buffer into empty wells of a plate, and start the reaction by adding 50 µL of 200 µM substrate. Include a substrate blank containing 50 µL of assay buffer and 50 µL of 200 µM substrate. Then read at excitiation and emission wavelengths of 380 nm and 460 nm, respectively, in kinetic mode for 5 minutes. The result was shown in Figure 1 and it was obvious that recombinant human antithrombin III significantly decreased thrombin activity. The inhibition IC50 was <8 nM.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitroPubMed: 25840743
  • iTRAQ-Based Quantitative Proteomics Reveals the New Evidence Base for Traumatic Brain Injury Treated with Targeted Temperature Managementpubmed:29247448
  • Detection of Angiotensin II and AT1 Receptor Concentrations in Keloid and Hypertrophic Scar.
  • An Agile Approach to Novel Recombinant Antithrombin Production for use in Biologics Development

Recommend products